RxDoctor Payments Data

Jill Smothers, NP

Nurse Practitioner · Colorado Springs, CONPI 1912104183

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,075 of the $7,989 with a category attached, or 63.5%. AstraZeneca accounts for 74.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $4,380 and has fallen 91.3% since, to $379 in 2025. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,989in general payments, 2019–2025

Across 156 payments — averaging $51.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$680
  • GSK$325
  • Lilly USA, LLC$115
  • Novartis$113
  • Sanofi$85
  • plus $727 from 17 others

What the payments were for

  • Speaking & faculty fees$5,07564%
  • Travel & lodging$571%
  • Food & beverage$2,85736%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,989 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$92,447
Medicare patients
84
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$37,289
FarxigaDapagliflozin Propanediol41$34,015
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$15,068
JardianceEmpagliflozin14$8,341
Lisdexamfetamine Dimesylate11$2,309
Levothyroxine Sodium97$1,242
Gabapentin43$1,045
Diclofenac Sodium40$990
Levetiracetam ErLevetiracetam13$988
Metoprolol Succinate48$887
Midodrine Hcl13$857
Tamsulosin Hcl42$777
Albuterol Sulfate HfaAlbuterol Sulfate24$750
Ipratropium Bromide17$686
Lisinopril84$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$5,944$49,08357 claims
PfizerEliquis$48$37,28931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →